Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder

NCT04221230 is registered in ClinicalTrials.gov with Neumora Therapeutics, Inc. as lead sponsor.

NCT NCT04221230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04221230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Lead sponsor
Neumora Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 3, 2020
Completion date
June 23, 2022
Enrollment
204 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder